REG - Oxford Biomedica PLC - Admission to Trading Application

Oxford BioMedicaAnnouncement

04/03/2026 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260304:nRSD3372Va&default-theme=true

RNS Number : 3372V  Oxford Biomedica PLC  04 March 2026

 

OXB

Admission to Trading Application

Oxford, UK - 04 March 2026: OXB (LSE: OXB), a quality and innovation-led cell
and gene therapy CDMO, today announces that application has been made to the
London Stock Exchange for the admission to trading of 92,381 ordinary shares
of 50 pence each in the Company (the "New Ordinary Shares").

The requested admission relates to ordinary shares which have been alloted
under:

 

·      OXB Long Term Incentive Plan (LTIP)

·      OXB Sharesave Scheme (SAYE)

·      OXB Employee Share Option Scheme (ESOS)

 

It is expected that admission becomes effective on 09 March 2026. The New
Ordinary Shares will rank pari passu in all respects with the Company's
existing ordinary shares in issue.

 

-Ends-

 

Enquiries:

​

OXB:

 

Natalie Walter, Chief Legal Officer and Group Company Secretary

T: +44 (0) 1865 783 000 / E: cosec@oxb.com

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development
and manufacturing organisation (CDMO) in cell and gene therapy with a mission
to enable its clients to deliver life changing therapies to patients around
the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class
capabilities range from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more
at www.oxb.com (http://www.oxb.com/)  and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica)  and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKQBNDBKDCNK



            Copyright 2019 Regulatory News Service, all rights reserved